Home ETF List About

Portfolio Holdings Detail for ISIN IE00BFNM3G45
Stock Name / FundiShares MSCI USA ESG Screened UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerSASU(USD) LSE
ETF TickerGPSA(GBP) LSE
ETF TickerSGAS(EUR) F
ETF TickerGPSA.LS(GBP) CXE
ETF TickerSASU.LS(USD) CXE
ETF TickerSASUz(USD) CXE
ETF TickerSGAS.DE(EUR) CXE
ETF TickerSASU.L(GBP) LSE
ETF TickerGPSA.L(GBP) LSE

Holdings detail for RPRX

Stock NameRoyalty Pharma Plc
TickerRPRX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINGB00BMVP7Y09
LEI549300FGFN7VOK8BZR03

Show aggregate RPRX holdings

News associated with RPRX

Royalty Pharma Expects At Least Mid-teens Average Annual Total Shareholder Return Over 2025-2030.
(RTTNews) - Royalty Pharma plc (RPRX) Thursday said it will host an Investor Day today, where senior executives will provide updates on the company's strategies aimed at driving shareholder value creation. - 2025-09-11 08:35:29
Maryland State Retirement & Pension System Trims Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)
Maryland State Retirement & Pension System lessened its position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 18.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 18,291 shares of the biopharmaceutical company’s stock after selling 4,133 shares during the quarter. […] - 2025-08-15 05:22:58
PNC Financial Services Group Inc. Acquires 859 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
PNC Financial Services Group Inc. boosted its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 7.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,665 shares of the biopharmaceutical company’s stock after purchasing an additional […] - 2025-08-15 04:48:59
Blair William & Co. IL Invests $212,000 in Royalty Pharma PLC (NASDAQ:RPRX)
Blair William & Co. IL bought a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,801 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. A number of other hedge […] - 2025-08-13 07:56:48
Deutsche Bank AG Sells 1,775,038 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
Deutsche Bank AG lessened its holdings in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 55.6% during the 1st quarter, Holdings Channel.com reports. The firm owned 1,414,926 shares of the biopharmaceutical company’s stock after selling 1,775,038 shares during the period. Deutsche Bank AG’s holdings in Royalty Pharma were worth $44,047,000 as of its most recent […] - 2025-08-13 05:54:50
Charles Schwab Investment Management Inc. Has $97.20 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)
Charles Schwab Investment Management Inc. cut its holdings in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 0.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 3,122,531 shares of the biopharmaceutical company’s stock after selling 9,097 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Royalty Pharma were worth $97,204,000 as […] - 2025-08-13 05:10:46
Royalty Pharma (NASDAQ:RPRX) Raised to Buy at Wall Street Zen
Royalty Pharma (NASDAQ:RPRX – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday. A number of other equities research analysts also recently weighed in on the company. Morgan Stanley boosted their target price on Royalty Pharma from $51.00 […] - 2025-08-11 03:50:55
Allianz Asset Management GmbH Has $6.03 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)
Allianz Asset Management GmbH reduced its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 64.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 193,591 shares of the biopharmaceutical company’s stock after selling 356,968 shares during the period. Allianz […] - 2025-07-28 07:00:47
Edgestream Partners L.P. Invests $659,000 in Royalty Pharma PLC (NASDAQ:RPRX)
Edgestream Partners L.P. acquired a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 21,158 shares of the biopharmaceutical company’s stock, valued at approximately $659,000. Other hedge funds and other institutional investors also […] - 2025-07-20 05:24:59
Cerity Partners LLC Boosts Stake in Royalty Pharma PLC (NASDAQ:RPRX)
Cerity Partners LLC raised its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 786.3% during the 1st quarter, Holdings Channel reports. The fund owned 153,846 shares of the biopharmaceutical company’s stock after purchasing an additional 136,487 shares during the period. Cerity Partners LLC’s holdings in Royalty Pharma were worth $4,789,000 as […] - 2025-07-17 05:00:57
Xponance Inc. Acquires 1,437 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
Xponance Inc. raised its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 3.7% in the first quarter, HoldingsChannel.com reports. The firm owned 40,133 shares of the biopharmaceutical company’s stock after buying an additional 1,437 shares during the period. Xponance Inc.’s holdings in Royalty Pharma were worth $1,249,000 as of its most […] - 2025-07-16 05:48:56
M&T Bank Corp Buys 5,500 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
M&T Bank Corp raised its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 23.4% in the 1st quarter, Holdings Channel reports. The firm owned 28,967 shares of the biopharmaceutical company’s stock after acquiring an additional 5,500 shares during the period. M&T Bank Corp’s holdings in Royalty Pharma were worth $902,000 at […] - 2025-07-15 06:23:30
Teacher Retirement System of Texas Cuts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)
Teacher Retirement System of Texas cut its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 10.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,364 shares of the biopharmaceutical company’s stock after selling 12,028 shares during the […] - 2025-07-09 05:33:01
Allspring Global Investments Holdings LLC Boosts Stake in Royalty Pharma PLC (NASDAQ:RPRX)
Allspring Global Investments Holdings LLC boosted its position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 4.0% in the first quarter, Holdings Channel.com reports. The institutional investor owned 561,724 shares of the biopharmaceutical company’s stock after acquiring an additional 21,729 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Royalty […] - 2025-07-03 06:09:03
11,210 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by Kentucky Retirement Systems Insurance Trust Fund
Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) in the first quarter, HoldingsChannel reports. The firm acquired 11,210 shares of the biopharmaceutical company’s stock, valued at approximately $349,000. Other hedge funds also recently bought and sold shares of the company. Louisbourg Investments Inc. […] - 2025-06-26 05:42:57
After Hours Most Active for Jun 24, 2025 : SNAP, NVDA, CMCSA, PLTR, INTC, SPR, AUR, RPRX, KVUE, MPW, GM, WMT
The NASDAQ 100 After Hours Indicator is down -.81 to 22,189.71. The total After hours volume is currently 173,627,396 shares traded.The following are the most active stocks for the after hours session: Snap Inc. (SNAP) is unchanged at $8.32, with 14,501,942 shares traded. SNAP's - 2025-06-24 17:24:56
Manning & Napier Advisors LLC Sells 44,505 Shares of Royalty Pharma PLC (NASDAQ:RPRX)
Manning & Napier Advisors LLC lessened its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 54.9% during the first quarter, HoldingsChannel.com reports. The firm owned 36,549 shares of the biopharmaceutical company’s stock after selling 44,505 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Royalty Pharma were worth $1,138,000 […] - 2025-06-24 05:20:57
After Hours Most Active for Jun 11, 2025 : PLTR, NVDA, AMZN, AAPL, RPRX, MCHPP
The NASDAQ 100 After Hours Indicator is up 14.32 to 21,875.12. The total After hours volume is currently 131,070,110 shares traded.The following are the most active stocks for the after hours session: Palantir Technologies Inc. (PLTR) is +0.25 at $136.64, with 5,538,416 shares t - 2025-06-11 17:24:56
Rhumbline Advisers Has $14.01 Million Position in Royalty Pharma plc (NASDAQ:RPRX)
Rhumbline Advisers lowered its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 0.9% during the first quarter, HoldingsChannel reports. The firm owned 449,964 shares of the biopharmaceutical company’s stock after selling 4,184 shares during the quarter. Rhumbline Advisers’ holdings in Royalty Pharma were worth $14,007,000 as of its most recent SEC […] - 2025-06-09 05:24:51
Lazard Asset Management LLC Reduces Holdings in Royalty Pharma plc (NASDAQ:RPRX)
Lazard Asset Management LLC lowered its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 4.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,457 shares of the biopharmaceutical company’s stock after selling 1,130 shares during the quarter. Lazard Asset […] - 2025-05-22 05:46:49
Royalty Pharma plc (NASDAQ:RPRX) Receives Average Rating of “Buy” from Brokerages
Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) has received a consensus recommendation of “Buy” from the five research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. […] - 2025-05-22 04:50:51
Captrust Financial Advisors Sells 14,499 Shares of Royalty Pharma plc (NASDAQ:RPRX)
Captrust Financial Advisors reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 49.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 14,829 shares of the biopharmaceutical company’s stock after selling 14,499 shares during the quarter. Captrust Financial Advisors’ holdings in Royalty Pharma were worth $378,000 as of […] - 2025-05-20 04:52:44
Analysts Predict 10% Gains Ahead For The Holdings of EUSA
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-19 07:59:43
Royalty Pharma (NASDAQ:RPRX) Raised to “Buy” at StockNews.com
Royalty Pharma (NASDAQ:RPRX – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Monday. Separately, Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. One equities research analyst has rated […] - 2025-05-14 02:14:45
Stifel Financial Corp Lowers Stake in Royalty Pharma plc (NASDAQ:RPRX)
Stifel Financial Corp reduced its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 11.4% in the fourth quarter, Holdings Channel reports. The firm owned 17,152 shares of the biopharmaceutical company’s stock after selling 2,200 shares during the period. Stifel Financial Corp’s holdings in Royalty Pharma were worth $438,000 at the end […] - 2025-05-13 04:50:58
Prudential Financial Inc. Has $488,000 Stake in Royalty Pharma plc (NASDAQ:RPRX)
Prudential Financial Inc. lowered its holdings in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 4.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 18,360 shares of the biopharmaceutical company’s stock after selling 955 shares during the period. Prudential Financial Inc.’s holdings in Royalty Pharma were worth $488,000 at the end of the […] - 2025-04-10 05:01:02
American Century Companies Inc. Boosts Holdings in Royalty Pharma plc (NASDAQ:RPRX)
American Century Companies Inc. grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 5.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 67,160 shares of the biopharmaceutical company’s stock after buying an additional 3,671 shares […] - 2025-04-10 04:26:56
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by JPMorgan Chase & Co.
JPMorgan Chase & Co. lifted its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 8.2% in the 4th quarter, Holdings Channel reports. The firm owned 1,395,242 shares of the biopharmaceutical company’s stock after purchasing an additional 105,824 shares during the quarter. JPMorgan Chase & Co.’s holdings in Royalty Pharma were worth $35,593,000 at […] - 2025-04-08 04:44:55
Schroder Investment Management Group Sells 354,483 Shares of Royalty Pharma plc (NASDAQ:RPRX)
Schroder Investment Management Group lowered its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 64.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 196,359 shares of the biopharmaceutical company’s stock after selling 354,483 shares during the quarter. Schroder Investment Management […] - 2025-04-06 05:29:08
Analysts Set Royalty Pharma plc (NASDAQ:RPRX) PT at $41.60
Shares of Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) have earned a consensus rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating […] - 2025-03-31 02:14:52

iShares MSCI USA ESG Screened UCITS ETF USD (Acc) RPRX holdings

DateNumber of RPRX Shares HeldBase Market Value of RPRX SharesLocal Market Value of RPRX SharesChange in RPRX Shares HeldChange in RPRX Base ValueCurrent Price per RPRX Share HeldPrevious Price per RPRX Share Held
2025-09-26 (Friday)112,255USD 3,933,415USD 3,933,415
2025-09-25 (Thursday)111,146USD 3,878,995USD 3,878,995
2025-09-24 (Wednesday)111,068USD 3,972,902USD 3,972,902
2025-09-18 (Thursday)109,579RPRX holding increased by 312USD 3,915,258RPRX holding increased by 20982USD 3,915,258312USD 20,982 USD 35.73 USD 35.64
2025-09-17 (Wednesday)109,267RPRX holding increased by 390USD 3,894,276RPRX holding increased by 37853USD 3,894,276390USD 37,853 USD 35.64 USD 35.42
2025-09-16 (Tuesday)108,877RPRX holding increased by 624USD 3,856,423RPRX holding increased by 51330USD 3,856,423624USD 51,330 USD 35.42 USD 35.15
2025-09-15 (Monday)108,253USD 3,805,093USD 3,805,093
2025-09-12 (Friday)108,045USD 3,928,516USD 3,928,516
2025-09-11 (Thursday)108,045USD 3,965,252USD 3,965,252
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RPRX by Blackrock for IE00BFNM3G45

Show aggregate share trades of RPRX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-18BUY312 35.730* 31.69
2025-09-17BUY390 35.640* 31.66
2025-09-16BUY624 35.420* 31.64
2025-08-15BUY52 36.350* 31.59
2025-08-13BUY27 36.460* 31.57
2025-07-31BUY130 36.800* 31.51
2025-07-29BUY520 37.270* 31.45
2025-07-28BUY96 37.060* 31.42
2025-07-25BUY156 36.670* 31.39
2025-07-24BUY76 36.590* 31.36
2025-07-23BUY182 36.010* 31.33
2025-07-22BUY104 36.100* 31.30
2025-07-18BUY160 35.590* 31.25
2025-07-17BUY156 35.470* 31.23
2025-07-07SELL-156 35.590* 31.09 Profit of 4,849 on sale
2025-07-02SELL-650 36.190* 30.99 Profit of 20,143 on sale
2025-06-27BUY83 35.870* 30.93
2025-06-26BUY78 35.270* 30.90
2025-06-24SELL-364 36.140* 30.83 Profit of 11,223 on sale
2025-06-18BUY208 34.910* 30.72
2025-06-17BUY78 34.560* 30.70
2025-06-16SELL-106 35.100* 30.67 Profit of 3,251 on sale
2025-06-13BUY234 34.840* 30.64
2025-06-12SELL-130 35.270* 30.61 Profit of 3,979 on sale
2025-06-11BUY286 34.050* 30.59
2025-06-06BUY78 33.780* 30.52
2025-06-05BUY364 33.750* 30.50
2025-06-04BUY50 33.440* 30.48
2025-06-03SELL-25 33.290* 30.46 Profit of 762 on sale
2025-05-30SELL-3,050 32.880* 30.42 Profit of 92,788 on sale
2025-05-29BUY70 32.640* 30.41
2025-05-27BUY454 32.690* 30.37
2025-05-23BUY360 32.450* 30.34
2025-05-22BUY182 32.310* 30.33
2025-05-19BUY150 34.250* 30.26
2025-05-16BUY75 34.020* 30.23
2025-05-15SELL-50 33.120* 30.20 Profit of 1,510 on sale
2025-05-14BUY25 32.290* 30.19
2025-05-13BUY50 32.820* 30.17
2025-05-12BUY150 33.350* 30.14
2025-05-09SELL-125 33.150* 30.12 Profit of 3,765 on sale
2025-05-08BUY50 33.100* 30.09
2025-05-07BUY75 32.750* 30.07
2025-05-02BUY2,775 32.890* 30.01
2025-04-30BUY875 32.820* 29.96
2025-04-29BUY222 32.710* 29.94
2025-04-28BUY175 32.540* 29.92
2025-04-25BUY450 32.200* 29.89
2025-04-24SELL-525 32.030* 29.88 Profit of 15,685 on sale
2025-04-23BUY475 31.690* 29.86
2025-04-22BUY200 32.190* 29.84
2025-04-17BUY275 32.600* 29.77
2025-04-15BUY250 32.450* 29.72
2025-04-11BUY416 31.950* 29.67
2025-04-09BUY156 32.270* 29.63
2025-04-08BUY936 30.850* 29.62
2025-04-07BUY297 31.030* 29.60
2025-04-04SELL-400 31.110* 29.59 Profit of 11,836 on sale
2025-04-02BUY3,536 31.280* 29.57
2025-04-01BUY26 31.170* 29.56
2025-03-31BUY175 31.130* 29.54
2025-03-28BUY100 31.370* 29.52
2025-03-27BUY48 31.650* 29.50
2025-03-26BUY25 31.560* 29.48
2025-03-25BUY275 33.760* 29.43
2025-03-24BUY312 33.750* 29.38
2025-03-21SELL-100 33.700* 29.33 Profit of 2,933 on sale
2025-03-20BUY400 33.500* 29.29
2025-03-19BUY72 33.410* 29.24
2025-03-18BUY880 33.410* 29.19
2025-03-17BUY175 33.020* 29.15
2025-03-14BUY1,300 32.770* 29.10
2025-03-13BUY250 32.680* 29.06
2025-03-12SELL-1,250 32.850* 29.02 Profit of 36,271 on sale
2025-03-11SELL-925 32.460* 28.97 Profit of 26,801 on sale
2025-03-10BUY275 32.750* 28.93
2025-03-07BUY50 33.010* 28.88
2025-03-05BUY375 33.770* 28.81
2025-03-04BUY425 33.320* 28.76
2025-03-03BUY800 33.860* 28.69
2025-02-28BUY650 33.640* 28.63
2025-02-27SELL-125 33.370* 28.56 Profit of 3,570 on sale
2025-02-25BUY925 33.690* 28.43
2025-02-21BUY100 33.420* 28.28
2025-02-18SELL-225 32.850* 28.08 Profit of 6,317 on sale
2025-02-14SELL-1,525 32.360* 27.95 Profit of 42,617 on sale
2025-02-13BUY25 32.460* 27.88
2025-02-12BUY246 32.340* 27.81
2025-02-07SELL-35 31.730* 27.61 Profit of 966 on sale
2025-02-06BUY475 31.400* 27.54
2025-02-05BUY125 31.450* 27.48
2025-02-04BUY150 31.260* 27.41
2025-02-03BUY150 31.330* 27.34
2025-01-31BUY275 31.580* 27.27
2025-01-29SELL-25 31.950* 27.10 Profit of 677 on sale
2025-01-28SELL-225 31.940* 27.01 Profit of 6,077 on sale
2025-01-27SELL-400 31.720* 26.92 Profit of 10,767 on sale
2025-01-24BUY300 31.060* 26.84
2025-01-23BUY50 30.620* 26.76
2024-12-10BUY1,250 25.590* 26.78
2024-12-09BUY150 26.010* 26.80
2024-12-06SELL-375 25.910* 26.82 Profit of 10,057 on sale
2024-12-05SELL-25 26.390* 26.83 Profit of 671 on sale
2024-12-03BUY125 26.340* 26.86
2024-11-27SELL-150 26.600* 26.88 Profit of 4,033 on sale
2024-11-26BUY525 26.290* 26.90
2024-11-25BUY71 26.470* 26.91
2024-11-22SELL-48 26.430* 26.92 Profit of 1,292 on sale
2024-11-21SELL-125 26.400* 26.94 Profit of 3,367 on sale
2024-11-20SELL-50 26.220* 26.96 Profit of 1,348 on sale
2024-11-19BUY25 26.010* 26.99
2024-11-18BUY228 25.800* 27.02
2024-11-11BUY75 26.360* 27.10
2024-11-11BUY75 26.360* 27.10
2024-11-07BUY71 26.520* 27.21
2024-11-07BUY71 26.520* 27.21
2024-11-06BUY600 26.640* 27.26
2024-11-06BUY600 26.640* 27.26
2024-11-05BUY125 27.540* 27.24
2024-11-05BUY125 27.540* 27.24
2024-11-04BUY50 27.200* 27.24
2024-11-04BUY50 27.200* 27.24
2024-11-01BUY72 27.100* 27.26
2024-11-01BUY72 27.100* 27.26
2024-10-30SELL-150 27.190* 27.30 Profit of 4,095 on sale
2024-10-30SELL-150 27.190* 27.30 Profit of 4,095 on sale
2024-10-29SELL-450 27.150* 27.33 Profit of 12,298 on sale
2024-10-29SELL-450 27.150* 27.33 Profit of 12,298 on sale
2024-10-28SELL-175 27.260* 27.34 Profit of 4,785 on sale
2024-10-28SELL-175 27.260* 27.34 Profit of 4,785 on sale
2024-10-21SELL-25 27.750* 0.00
2024-10-21SELL-25 27.750* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RPRX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19877,43501,269,34869.1%
2025-09-18854,1562551,225,70969.7%
2025-09-17890,42801,130,88978.7%
2025-09-16849,69101,371,04262.0%
2025-09-151,310,0518751,800,47672.8%
2025-09-121,066,1208001,339,29279.6%
2025-09-111,220,1202831,532,65679.6%
2025-09-101,195,1197901,440,33383.0%
2025-09-091,259,8539241,521,80482.8%
2025-09-081,967,2801,0943,312,54759.4%
2025-09-052,792,92604,789,48758.3%
2025-09-04649,49701,396,64246.5%
2025-09-03741,51103,964,24418.7%
2025-09-021,164,4616211,836,12263.4%
2025-08-29568,8486441,099,44151.7%
2025-08-28343,4431,229665,67251.6%
2025-08-27718,529151,134,79763.3%
2025-08-26376,8063,158782,11648.2%
2025-08-25523,36001,666,11631.4%
2025-08-22416,9751,403983,55642.4%
2025-08-21515,9061789,60565.3%
2025-08-20668,9345571,359,61949.2%
2025-08-19282,3631,211801,13935.2%
2025-08-18470,777713735,14364.0%
2025-08-15370,8860849,95543.6%
2025-08-14437,27101,270,82534.4%
2025-08-13450,93002,187,21920.6%
2025-08-12378,7083211,366,73627.7%
2025-08-11566,6033221,321,77142.9%
2025-08-08732,3041,1411,058,55269.2%
2025-08-07637,7791411,478,11943.1%
2025-08-06968,026951,335,30672.5%
2025-08-05817,147971,153,95670.8%
2025-08-04562,562677830,96467.7%
2025-08-01356,771847641,24655.6%
2025-07-31550,713210657,91283.7%
2025-07-30529,655432816,35164.9%
2025-07-29600,85925752,37279.9%
2025-07-28682,7281,073824,97582.8%
2025-07-25351,99350514,20168.5%
2025-07-24396,41057557,22971.1%
2025-07-23289,2172,996787,22036.7%
2025-07-22460,4210666,17169.1%
2025-07-21489,8451,682693,05470.7%
2025-07-18355,3760587,43460.5%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.